Monday, May 16

7:00 p.m.-8:00 p.m.   Opening Keynote Session  
Metropolitan Ballroom 1

Welcome Remarks  
Session Chairperson: Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN

Keynote Address  
Metropolitan Ballroom 1  
The discovery of next-generation cancer targets and therapeutics  
William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA

8:00 p.m. – 10:00 p.m.   Welcome Reception  
Metropolitan Ballroom 2-4

Tuesday, May 17

7:00 a.m.-8:00 a.m.   Continental Breakfast  
Metropolitan Ballroom 5-7  
If applicable, please follow signs for Networking Roundtables.

8:00 a.m.-10:00 a.m.   Plenary Session 1: Targeting Programmed Cell Death and Autophagy  
Metropolitan Ballroom 1  
Session Chairperson: William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA

8:00 a.m.-8:30 a.m.  Mcl-1 inhibitors for the treatment of cancer  
Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN

8:30 a.m.-9:00 a.m.  Mechanistic studies of IAP inhibitors  
Wayne J. Fairbrother, Genentech, Inc., South San Francisco, CA

9:00 a.m.-9:30 a.m.  Pharmacological intervention in p53 regulation by inhibitors of MDM2 and ATM  
Lyubomir T. Vassilev, EMD Serono R&D Institute, Inc., Billerica, MA

9:30 a.m.-10:00 a.m.  Autophagy prevents fatal nucleotide pool depletion in Ras-driven cancer cells  
Eileen P. White, Rutgers-The Cancer Institute of New Jersey, New Brunswick, NJ

10:00 a.m.-10:30 a.m.   Break  
Metropolitan Ballroom Pre-Function
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:30 a.m.-12:30 p.m. | **Plenary Session 2: Targeting Pathway Addiction and Resistance**  
Metropolitan Ballroom 1  
**Session Chairperson: Paul Workman,** The Institute of Cancer Research, London, England |
| 10:30 a.m.-11:00 a.m. | Genomic approaches to drug discovery  
**Todd R. Golub,** Broad Institute of MIT and Harvard, Cambridge, MA |
| 11:00 a.m.-11:30 a.m. | Addiction of prostate cancer to androgen receptor  
**Yan Dong,** Tulane University, New Orleans, LA |
| 11:30 a.m.-12:00 p.m. | Therapeutic resistance and feedback loops  
**Jean J. Zhao,** Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA |
| 12:00 p.m.-12:30 p.m. | Non-mutational resistance to anti-cancer drugs  
**Jeffrey Settleman,** Calico Life Sciences, South San Francisco, CA |
| 12:30 p.m.-3:00 p.m. | **Poster Session A with Lunch**  
Metropolitan Ballroom 2-4 (Posters)  
Metropolitan Ballroom 5-7 (Lunch) |
| 3:00 p.m.-5:00 p.m. | **Plenary Session 3: Targeting Genomic Instability**  
Metropolitan Ballroom 1  
**Session Chairperson: Frank McCormick,** UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA |
| 3:00 p.m.-3:40 p.m. | Targeting the DNA damage response in cancer: Progress in the clinic  
**Timothy A. Yap,** Royal Marsden Hospital and The Institute of Cancer Research, Sutton, England |
| 3:40 p.m.-4:20 p.m. | Discovery and characterization of potent and selective inhibitors of ATR kinase as anti-cancer agents  
**John Pollard,** Vertex Pharmaceuticals (Europe) Ltd., Abingdon, England |
| 4:20 p.m.-5:00 p.m. | CHK1 inhibitors: From concept to clinic  
**Michelle D. Garrett,** University of Kent, Canterbury, England |
| 5:00 p.m. | **Evening on Own** |
**Wednesday, May 18**

7:00 a.m.-8:00 a.m.  **Continental Breakfast**  
Metropolitan Ballroom 5-7  
If applicable, please follow signs for Networking Rountables.

8:00 a.m.-10:00 a.m.  **Plenary Session 4: Targeting Multiple Hallmarks of Cancer**  
Metropolitan Ballroom 1  
**Session Chairperson:** William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, MA

8:00 a.m.-8:30 a.m.  
Targeting Ras  
**Frank McCormick,** UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

8:30 a.m.-9:00 a.m.  
Novel approaches for targeting MYC  
**William P. Tansey,** Vanderbilt University, Nashville, TN

9:00 a.m.-9:30 a.m.  
Targeting molecular chaperone and stress pathways to hit multiple cancer hallmarks and overcome resistance  
**Paul Workman,** The Institute of Cancer Research, London, England

9:30 a.m.-9:45 a.m.  
IACS-010759 a novel inhibitor of oxidative phosphorylation advancing into first-in-human studies to exploit metabolic vulnerabilities*  
**Philip Jones,** The University of Texas MD Anderson Cancer Center, Houston, TX

9:45 a.m.-10:00 a.m.  
Towards a cancer dependency map*  
**Aviad Tsherniak,** Broad Institute of MIT and Harvard, Cambridge, MA

10:00 a.m.-10:30 a.m.  **Break**  
Metropolitan Ballroom Pre-Function

10:30 a.m.-12:30 p.m.  **Plenary Session 5: Immunotherapy (Part 1)**  
Metropolitan Ballroom 1  
**Session Chairperson:** Jane Grogan, Genentech Inc., South San Francisco, CA

10:30 a.m.-11:00 a.m.  
Adoptive T cell therapy  
**Carl H. June,** Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA

11:00 a.m.-11:30 a.m.  
Building better T cells for targeting and eliminating tumors  
**Philip D. Greenberg,** Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA

11:30 a.m.-12:00 p.m.  
Novel insights into T cell recognition and regulation at the tumor site  
**Andrew J.S. Furness,** UCL Cancer Institute and Royal Marsden Hospital, London, United Kingdom

12:00 p.m.-12:30 p.m.  
Targeting molecules mediating the dialogue between epithelial cells and local T cells  
**Adrian Hayday,** The Francis Crick Institute, London, England

*Short talks from proffered abstracts.*
12:30 p.m.-3:00 p.m. Lunch on Own/Free Time

3:00 p.m.-5:00 p.m. **Plenary Session 6: Immunotherapy (Part 2)**
Metropolitan Ballroom 1
**Session Chairperson: Carl H. June,** Abramson Cancer Center of University of Pennsylvania, Philadelphia, PA

3:00 p.m.-3:30 p.m. CTLA4 antibodies and beyond
**James P. Allison,** The University of Texas MD Anderson Cancer Center, Houston, TX

3:30 p.m.-4:00 p.m. The immunoreceptor TIGIT limits anti-tumor T cell responses
**Jane Grogan,** Genentech Inc., South San Francisco, CA

4:00 p.m.-4:30 p.m. Enhancing anti-tumor immunity through selective inhibition of IDO11†
**Reid Huber,** Incyte Corporation, Wilmington, DE

4:30 p.m.-4:45 p.m. Molecular characterization of in vitro exhausted T cells*†
**William Hastings,** Novartis Institute for Biomedical Research, Cambridge, MA

4:45 p.m.-5:00 p.m. Small molecule-mediated activation of Ras elicits inhibition of MAPK and PI3K signaling through pathway feedback*
**Jennifer E. Howes,** Vanderbilt University, Nashville, TN

5:00 p.m.-7:30 p.m. **Poster Session B and Reception**
Metropolitan Ballroom 2-4

7:30 p.m. Evening on Own

---

**Thursday, May 19**

7:00 a.m.-8:00 a.m. Continental Breakfast
Metropolitan Ballroom 5-7
If applicable, please follow signs for Networking Roundtables.

8:00 a.m.-10:00 a.m. **Plenary Session 7: Targeting Epigenetics**
Metropolitan Ballroom 1
**Session Chairperson: Jeffrey Settleman,** Calico Life Sciences, South San Francisco, CA

8:00 a.m.-8:30 a.m. Transcriptional regulators as cancer dependencies
**Christopher R. Vakoc,** Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

8:30 a.m.-9:00 a.m. Targeting cancers with deletion of the p16/p14 tumor suppressor locus
**Kevin Marks,** Agios Pharmaceuticals Inc., Cambridge, MA

---

*Short talks from proffered abstracts
†Not eligible for CME credit
9:00 a.m.-9:30 a.m.  Targeted inhibition of the menin-MLL interaction in cancer
Jolanta E. Grembecka, University of Michigan, Ann Arbor, MI

9:30 a.m.-10:00 a.m.  Protein methyltransferase inhibitors as precision cancer therapeutics: From bench to bedside to bench
Robert A. Copeland, Epizyme, Inc., Cambridge, MA

10:00 a.m.-10:15 a.m.  Break
Metropolitan Ballroom Pre-Function

10:15 a.m.-12:15 p.m.  Plenary Session 8: Targeting Oncoproteins for Degradation
Metropolitan Ballroom 1
Session Chairperson: Robert A. Copeland, Epizyme, Inc., Cambridge, MA

10:15 a.m.-10:45 a.m.  PROTACs as a therapeutic strategy to induce protein degradation
Craig M. Crews, Yale University, New Haven, CT

10:45 a.m.-11:15 a.m.  Targeting undruggable proteins for degradation with small molecules
William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, MA

11:15 a.m.-11:45 a.m.  Targeting hormone receptors for degradation: Nuclear receptor downregulation as a therapeutic approach in cancer
Donald P. McDonnell, Duke University Medical Center, Durham, NC

11:45 a.m.-12:15 p.m.  Phthalimide conjugation as a strategy for targeted protein degradation
Georg E. Winter, Dana-Farber Cancer Institute, Boston, MA

12:15 p.m.  Departure